Literature DB >> 15352068

Lentiviral vectors for treating and modeling human CNS disorders.

Mimoun Azzouz1, Susan M Kingsman, Nicholas D Mazarakis.   

Abstract

Vectors based on lentiviruses efficiently deliver genes into many different types of primary neurons from a broad range of species including man and the resulting gene expression is long term. These vectors are opening up new approaches for the treatment of neurological diseases such as Parkinson's disease (PD), Huntington's disease (HD), and motor neuron diseases (MNDs). Numerous animal studies have now been undertaken with these vectors and correction of disease models has been obtained. Lentiviral vectors also provide a new strategy for in vivo modeling of human diseases; for example, the lentiviral-mediated overexpression of mutated human alpha-synuclein or huntingtin genes in basal ganglia induces neuronal pathology in animals resembling PD and HD in man. These vectors have been refined to a very high level and can be produced safely for the clinic. This review will describe the general features of lentiviral vectors with particular emphasis on vectors derived from the non-primate lentivirus, equine infectious anemia virus (EIAV). It will then describe some key examples of genetic correction and generation of genetic animal models of neurological diseases. The prospects for clinical application of lentiviral vectors for the treatment of PD and MNDs will also be outlined. Copyright 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2004        PMID: 15352068     DOI: 10.1002/jgm.600

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  15 in total

Review 1.  Human gene therapy and imaging in neurological diseases.

Authors:  Andreas H Jacobs; Alexandra Winkler; Maria G Castro; Pedro Lowenstein
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-12       Impact factor: 9.236

Review 2.  Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS.

Authors:  Seung T Lim; Mikko Airavaara; Brandon K Harvey
Journal:  Pharmacol Res       Date:  2009-10-17       Impact factor: 7.658

Review 3.  Non-viral therapeutic approaches to ocular diseases: An overview and future directions.

Authors:  Rahel Zulliger; Shannon M Conley; Muna I Naash
Journal:  J Control Release       Date:  2015-10-09       Impact factor: 9.776

4.  HIV-1-based defective lentiviral vectors efficiently transduce human monocytes-derived macrophages and suppress replication of wild-type HIV-1.

Authors:  Lingbing Zeng; Vicente Planelles; Ziye Sui; Suzanne Gartner; Sanjay B Maggirwar; Stephen Dewhurst; Linbai Ye; Vivek R Nerurkar; Richard Yanagihara; Yuanan Lu
Journal:  J Gene Med       Date:  2006-01       Impact factor: 4.565

5.  Dose-dependent neuroprotection of VEGF₁₆₅ in Huntington's disease striatum.

Authors:  Stuart M Ellison; Antonio Trabalza; Veronica Tisato; Evangelos Pazarentzos; Shirley Lee; Vasiliki Papadaki; Despoina Goniotaki; Sarah Morgan; Nazanin Mirzaei; Nicholas D Mazarakis
Journal:  Mol Ther       Date:  2013-06-25       Impact factor: 11.454

6.  Lentiviral Vector Gene Transfer of Endostatin/Angiostatin for Macular Degeneration (GEM) Study.

Authors:  Peter A Campochiaro; Andreas K Lauer; Elliott H Sohn; Tahreem A Mir; Stuart Naylor; Matthew C Anderton; Michelle Kelleher; Richard Harrop; Scott Ellis; Kyriacos A Mitrophanous
Journal:  Hum Gene Ther       Date:  2016-09-26       Impact factor: 5.695

Review 7.  Therapeutic gene silencing in neurological disorders, using interfering RNA.

Authors:  G Scott Ralph; Nicholas D Mazarakis; Mimoun Azzouz
Journal:  J Mol Med (Berl)       Date:  2005-03-10       Impact factor: 4.599

8.  Correction of tau mis-splicing caused by FTDP-17 MAPT mutations by spliceosome-mediated RNA trans-splicing.

Authors:  Teresa Rodriguez-Martin; Karen Anthony; Mariano A Garcia-Blanco; S Gary Mansfield; Brian H Anderton; Jean-Marc Gallo
Journal:  Hum Mol Genet       Date:  2009-06-04       Impact factor: 6.150

Review 9.  The cell biology of rabies virus: using stealth to reach the brain.

Authors:  Matthias J Schnell; James P McGettigan; Christoph Wirblich; Amy Papaneri
Journal:  Nat Rev Microbiol       Date:  2010-01       Impact factor: 60.633

Review 10.  Gene delivery with viral vectors for cerebrovascular diseases.

Authors:  Yu Gan; Zheng Jing; Ruth Anne Stetler; Guodong Cao
Journal:  Front Biosci (Elite Ed)       Date:  2013-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.